PureTech Health PLC (NASDAQ:PRTC) — Market Cap & Net Worth
Market Cap & Net Worth: PureTech Health PLC (PRTC)
PureTech Health PLC (NASDAQ:PRTC) has a market capitalization of $421.98 Million ($421.98 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13419 globally and #3067 in its home market, demonstrating a 2.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PureTech Health PLC's stock price $18.14 by its total outstanding shares 24168404 (24.17 Million). Analyse cash flow conversion of PureTech Health PLC to see how efficiently the company converts income to cash.
PureTech Health PLC Market Cap History: 2020 to 2026
PureTech Health PLC's market capitalization history from 2020 to 2026. Data shows change from $1.31 Billion to $438.41 Million (-12.88% CAGR).
Index Memberships
PureTech Health PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #348 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1268 of 3165 |
Weight: PureTech Health PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PureTech Health PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PureTech Health PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
92.41x
PureTech Health PLC's market cap is 92.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.34x
PureTech Health PLC's market cap is 8.34 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.31 Billion | $8.34 Million | $5.99 Million | 156.47x | 218.06x |
| 2021 | $894.23 Million | $9.98 Million | -$60.56 Million | 89.61x | N/A |
| 2022 | $770.97 Million | $2.09 Million | -$50.35 Million | 368.89x | N/A |
| 2023 | $681.07 Million | $3.33 Million | -$65.70 Million | 204.52x | N/A |
| 2024 | $446.15 Million | $4.83 Million | $53.51 Million | 92.41x | 8.34x |
Competitor Companies of PRTC by Market Capitalization
Companies near PureTech Health PLC in the global market cap rankings as of May 4, 2026.
Key companies related to PureTech Health PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PureTech Health PLC Historical Marketcap From 2020 to 2026
Between 2020 and today, PureTech Health PLC's market cap moved from $1.31 Billion to $ 438.41 Million, with a yearly change of -12.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $438.41 Million | +9.01% |
| 2025 | $402.16 Million | -9.86% |
| 2024 | $446.15 Million | -34.49% |
| 2023 | $681.07 Million | -11.66% |
| 2022 | $770.97 Million | -13.78% |
| 2021 | $894.23 Million | -31.48% |
| 2020 | $1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PureTech Health PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $421.98 Million USD |
| MoneyControl | $421.98 Million USD |
| MarketWatch | $421.98 Million USD |
| marketcap.company | $421.98 Million USD |
| Reuters | $421.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more